Stem Genomics is a biotech company, located in France and in the USA, specialized in the design of innovative testing technologies for stem cells.
A spin-out of the Institute for Regenerative Medicine & Biotherapy (IRMB) and co-founded by Prof. John de Vos and Dr. Said Assou, experts in stem cell genomic integrity, Stem Genomics has emerged from a prestigious scientific environment.
Located at the heart of the University Hospital Centre of Montpellier, the IRMB houses research groups working on basic stem cell research and innovative applications for regenerative therapy with the aim of facilitating the transfer from research to clinical applications.
Founded in 2018, we work with +150 clients worldwide, from academic institutions to biotech companies and core facilities. We service our North American clients from our laboratory based in the Research Triangle in Durham, North Carolina, and our European and other international clients from our headquarters in Montpellier, France.

Stem Genomics is a team of passionate and committed individuals whose aim is to support research scientists in achieving qualitative and reliable cell lines for their work.
We have developed in-house expertise in stem cells and in innovative genetic stability assay technologies which enable us to perform most of our tests on our own platform. In parallel, our R&D team is continuously developing latest generation quality controls assays.
We pride ourselves on our reactivity and availability in our relationship with our clients throughout the process.

Technologies we have selected for stem cell characterization:
- Digital PCR (dPCR) is the most accurate PCR method for assessing the genetic integrity of stem cells through the detection of Copy Number Variants (CNVs). It is ideal for regular in-process controls and fast clone screening.
- G-banding karyotyping is helpful in providing an exhaustive structural and numerical variant analysis.
- Next-Generation Sequencing (NGS) offers a hypothesis-free approach that does not require prior knowledge of sequence information. NGS enables the simultaneous analysis of numerous genes, making it both feasible and cost effective. It is particularly well-suited to key stages in the workflow such as cell line acquisition, banking and/or end of workflow.

Media

---